-
公开(公告)号：EP2189537B1
公开(公告)日：2014-10-08
申请号：EP08792016.1
申请日：2008-07-31
发明人： ITOKAWA, Masanari , MIYATA, Toshio , ARAI, Makoto
IPC分类号： C12Q1/68 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , A61K45/00 , A61P25/18 , C12N15/09 , G01N30/88 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/527 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/6893 , G01N2333/988
-
2.发明公开
公开(公告)号：EP2272822A1
公开(公告)日：2011-01-12
申请号：EP09729173.6
申请日：2009-03-31
IPC分类号： C07C235/74 , A61K31/167 , A61K31/196 , A61K31/245 , A61K31/34 , A61K31/36 , A61K31/385 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/4409 , A61K31/47 , A61P3/10 , A61P7/02
CPC分类号： C07C235/16 , C07C233/56 , C07C233/88 , C07C235/68 , C07C317/44 , C07C323/60 , C07C2601/14 , C07C2601/20 , C07D207/325 , C07D213/40 , C07D213/74 , C07D215/12 , C07D231/12 , C07D261/08 , C07D263/32 , C07D307/38 , C07D307/79 , C07D317/50 , C07D333/06
摘要： The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula.
Each symbol is defined as those in the specification.摘要翻译： 本发明涉及具有纤溶酶原激活物抑制剂-1（PAI-1）抑制活性的新型化合物和包含该化合物作为活性成分的PAI-1抑制剂。 本发明还涉及对PAI-1活性具有抑制作用的药物组合物，并且可用于预防和治疗与PAI-1活性相关的各种疾病。 该新化合物由以下通式表示。 每个符号被定义为说明书中的符号。
-
公开(公告)号：EP3623472A1
公开(公告)日：2020-03-18
申请号：EP18798161.8
申请日：2018-05-11
发明人： TATENO, Toshihiro , YOKOTA, Motoi , HIDESAKI, Tomonori , ARAKI, Tadashi , SHINDO, Atsunori , MATSUMOTO, Yoshiko , MIYATA, Toshio , HONJO, Masaru
摘要： A recombinant microorganism includes a gene encoding a pyridoxine dehydrogenase, a gene encoding a pyridoxamine synthetase having an enzymatic activity of synthesizing pyridoxamine from pyridoxal, and a gene encoding an amino acid regeneration enzyme having an enzymatic activity of regenerating an amino acid consumed by the pyridoxamine synthetase, in which at least two of the gene encoding the pyridoxine dehydrogenase, the gene encoding the pyridoxamine synthetase, or the gene encoding the amino acid regeneration enzyme, are introduced from outside of a bacterial cell, or are endogenous to the bacterial cell and have an enhanced expression. In addition, a recombinant microorganism into which a gene encoding a pyridoxine dehydrogenase is introduced is provided.
-
4.发明公开
公开(公告)号：EP2415755A1
公开(公告)日：2012-02-08
申请号：EP10758123.3
申请日：2010-03-31
IPC分类号： C07C233/81 , A61K31/196 , A61K31/341 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4418 , A61K31/4525 , A61P1/16 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/14 , A61P11/00 , A61P13/12 , A61P25/00 , A61P25/28 , A61P27/02 , A61P35/00 , A61P35/04
CPC分类号： C07D409/12 , C07C233/81 , C07D213/56 , C07D215/14 , C07D217/16 , C07D295/192 , C07D307/42 , C07D307/54 , C07D307/66 , C07D333/24 , C07D333/36 , C07D405/04 , C07D405/10 , C07D405/12
摘要： The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.
摘要翻译： 本发明提供了具有纤溶酶原激活物抑制剂-1抑制活性的新化合物和包含该化合物作为活性成分的PAI-1抑制剂。 本发明还提供了对PAI-1活性具有抑制作用并且有效预防和治疗与PAI-1活性相关的各种疾病的药物组合物。
-
公开(公告)号：EP2189537A1
公开(公告)日：2010-05-26
申请号：EP08792016.1
申请日：2008-07-31
申请人： TOKAI UNIVERSITY EDUCATIONAL SYSTEM , Tokyo Metropolitan Organization for Medical Research , Renascience CO., LTD. , Medical and Biological Laboratories Co., Ltd.
发明人： ITOKAWA, Masanari , MIYATA, Toshio , ARAI, Makoto
IPC分类号： C12Q1/68 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , A61K45/00 , A61P25/18 , C12N15/09 , G01N30/88 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/527 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/6893 , G01N2333/988
摘要： The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
摘要翻译： 本发明提供一种用于诊断精神分裂症的方法，以及用于该方法的精神分裂症诊断试剂或装置。 本发明还提供了精神分裂症的治疗或改善剂，其对治疗或改善精神分裂症有效。 用于精神分裂症的治疗或改善剂含有羰基清除剂或羰基修饰的蛋白质形成抑制剂作为活性成分。 根据本发明的诊断精神分裂症的方法包括测量受试者中的至少一个参数，所述参数选自：（1）乙二醛酶I基因的遗传异常; （2）生物样品中乙二醛酶I的表达水平或活性; （3）作为用羰基化合物修饰的蛋白质的羰基化合物或羰基修饰蛋白质的量; 和（4）生物样品中吡哆醛的量。
-
6.发明公开
公开(公告)号：EP3623471A1
公开(公告)日：2020-03-18
申请号：EP18797661.8
申请日：2018-05-11
发明人： TATENO, Toshihiro , HIDESAKI, Tomonori , ARAKI, Tadashi , SHINDO, Atsunori , MATSUMOTO, Yoshiko , MIYATA, Toshio , HONJO, Masaru
摘要： Provided are a recombinant microorganism comprising: a gene encoding a pyridoxine oxidase; and a gene encoding a pyridoxamine synthetase having an enzymatic activity of synthesizing pyridoxamine from pyridoxal, in which each of the gene encoding a pyridoxine oxidase and the gene encoding a pyridoxamine synthetase is introduced from outside of a bacterial cell, or is endogenous to the bacterial cell and has an enhanced expression, and a method of producing pyridoxamine or a salt thereof from pyridoxine or a salt thereof using the recombinant microorganism.
-
7.发明授权
公开(公告)号：EP2990057B1
公开(公告)日：2019-03-20
申请号：EP14785000.2
申请日：2014-04-15
发明人： ANDO, Kiyoshi , YAHATA, Takashi , MIYATA, Toshio
IPC分类号： A61K45/06 , A61K45/00 , A61K31/192 , A61K31/196 , A61K31/341 , A61K31/381 , A61K31/40 , A61K31/402 , A61K31/4025 , A61K31/404 , A61K31/4418 , A61K31/445 , A61K31/4525 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/506 , A61P7/00 , A61P35/00 , A61P43/00
-
公开(公告)号：EP3424501A1
公开(公告)日：2019-01-09
申请号：EP17760149.9
申请日：2017-03-02
发明人： MIYATA, Toshio , KURE, Shigeo , KURIYAMA, Shinichi , SATO, Hiroki
摘要： The present invention provides a composition effective in improving symptoms of autism spectrum disorder. The composition contains at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof as an active substance. The composition may be used in combination with at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof.
-
公开(公告)号：EP2990057A1
公开(公告)日：2016-03-02
申请号：EP14785000.2
申请日：2014-04-15
发明人： ANDO, Kiyoshi , YAHATA, Takashi , MIYATA, Toshio
CPC分类号： A61K31/341 , A61K31/192 , A61K31/196 , A61K31/381 , A61K31/40 , A61K31/402 , A61K31/4025 , A61K31/404 , A61K31/4418 , A61K31/445 , A61K31/4525 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/506 , A61K45/06
摘要： Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.
摘要翻译： 提供了用作控制肿瘤干细胞的药剂的活性成分的纤溶酶原激活物抑制剂-1抑制剂（PAI-1抑制剂）的新用途，用于增强抗肿瘤剂的抗肿瘤作用的药剂， 用于肿瘤化疗，干细胞保护药物或造血障碍改善剂。
-
10.发明公开PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING 审中-公开PHENYLENDERIVAT MIT TETRAZOLRING ODER THIAZOLIDINDIONRING
公开(公告)号：EP1679310A1
公开(公告)日：2006-07-12
申请号：EP04773615.2
申请日：2004-09-29
发明人： YANAGISAWA, Hiroaki, c/o Sankyo Company, Limited , AMEMIYA, Yoshiya, c/o Sankyo Company, Limited , KUROKAWA, Kiyoshi , MIYATA, Toshio
IPC分类号： C07D257/04
CPC分类号： C07D277/34 , A61K31/41 , A61K31/426 , A61K31/437 , A61K31/4709 , A61K31/5377 , A61K31/538 , A61K31/541 , A61K31/5415 , C07D257/04 , C07D401/10 , C07D413/10 , C07D417/10 , C07D471/04
摘要： The present invention provides a compound represented by the following formula (I)
wherein A is a cyclic group etc., B is a 1H-tetrazol-5-yl group or a 2,4-dioxothiazolidin-5-yl group, and Y is a single bond or a C6-10 arylene group, or a pharmacologically acceptable salt thereof or an ester thereof. phthalidyl group, "Tez" shows a 1H-tetrazol-5-yl group, "Tzd" shows a 2,4-dioxothiazolidin-5-yl group, and "-" shows a single bond.摘要翻译： 本发明提供由下式（I）表示的化合物，其中A为环状基团等，B为1H-四唑-5-基或2,4-二氧代噻唑烷-5-基，Y为 单键或C6-10亚芳基，或其药学上可接受的盐或其酯。 酞嗪基，“Tez”表示1H-四唑-5-基，“Tzd”表示2,4-二氧代噻唑烷-5-基，“ - ”表示单键。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
